JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online September 15, 2008, 10.2967/jnumed.107.050260
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.050260v1
49/10/1694    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doue, T.
Right arrow Articles by Matsubara, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doue, T.
Right arrow Articles by Matsubara, H.
Journal of Nuclear Medicine Vol. 49 No. 10 1694-1700
© 2008 by Society of Nuclear Medicine
doi: 10.2967/jnumed.107.050260

Basic Science Investigation

Cardioprotective Effects of Erythropoietin in Rats Subjected to Ischemia–Reperfusion Injury: Assessment of Infarct Size with 99mTc-Annexin V

Tomoki Doue1,2, Katsuichi Ohtsuki1,2, Kazuma Ogawa3, Masashi Ueda4, Akihiro Azuma1, Hideo Saji5, Harry W. Strauss6 and Hiroaki Matsubara1

1 Department of Cardiology and Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 2 Department of Medicine, Meiji University of Integrative Medicine, Nantan, Japan; 3 Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan; 4 Radioisotopes Research Laboratory, Kyoto University Hospital Faculty of Medicine, Kyoto University, Kyoto, Japan; 5 Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan; and 6 Division of Nuclear Medicine, Department of Radiology, Memorial Sloan-Kettering Hospital, New York, New York

Correspondence: For correspondence or reprints contact: Tomoki Doue, Department of Medicine, Meiji University of Integrative Medicine, Hiyoshi-cho Nantan, Kyoto, 629-0392, Japan. E-mail: doue{at}meiji-u.ac.jp

Administration of erythropoietin (EPO) during or immediately after myocardial ischemia can reduce subsequent myocardial apoptosis, a key phenomenon in myocardial ischemia–reperfusion injury. In this study, we assessed the effect of EPO on 99mTc-annexin V myocardial uptake and whether the accumulation of 99mTc-annexin V can predict cardiac remodeling and functional deterioration. Methods: Eighteen rats with left coronary artery (LCA) occlusion were randomized to receive either an intravenous injection of EPO (EPO group) or saline (nontherapy [nT] group) immediately after release of the occlusion. After 20 min of LCA occlusion and 30 min of reperfusion, the rats were injected with 99mTc-annexin V. One hour after 99mTc-annexin V injection, the LCA was reoccluded and 201Tl was injected intravenously, and the rats were sacrificed 1 min later. The heart was removed and sectioned, and dual-tracer autoradiography was performed to evaluate the distribution of the area at risk (defined on the thallium autoradiograph) and the area of apoptosis (defined on the annexin autoradiograph). Adjacent histologic specimens had deoxyuridine triphosphate nick-end labeling (TUNEL) staining to confirm the presence of apoptosis and were compared with autoradiography. Another 16 rats were randomized to EPO and nT groups and underwent echocardiography immediately after release of the LCA occlusion and at 2 and 4 wk after surgery. Results: The areas of 99mTc-annexin V accumulation in the EPO group were smaller than those in the nT group, though the 201Tl defect areas of these 2 groups were comparable (area ratio, 0.318 ± 0.038 vs. 0.843 ± 0.051, P < 0.001, for annexin and 24.8 ± 2.1 vs. 25.9 ± 2.6 mm2, P = NS, for thallium). 99mTc-annexin V accumulation correlated with the density of TUNEL-positive cells (r = 0.886, P < 0.001). In the nT group, left ventricular end-diastolic dimension (Dd) increased from baseline at 2 wk by 34.7% ± 3.8% and remained stable at 34.9% ± 5.0% at 4 wk after coronary occlusion. In the EPO group, Dd increased by 8.5% ± 2.1% (P < 0.01 vs. nT at 2 wk) and 13.2% ± 2.8% (P < 0.01 vs. nT at 4 wk). In the nT group, the left ventricular percentage of fractional shortening decreased by 42.2% ± 3.4% and 52.9% ± 3.4% at 2 and 4 wk, respectively, whereas in the EPO group it decreased 9.0% ± 1.9% at 2 wk (P < 0.01 vs. nT at 2 wk) and 11.1% ± 6.7% at 4 wk (P < 0.01 vs. nT at 4 wk). Conclusion: This study demonstrated that a single treatment with EPO immediately after release of coronary ligation suppressed cardiac remodeling and functional deterioration. 99mTc-annexin V autoradiographs and TUNEL staining confirm that this change is due to a decrease in the extent of myocardial apoptosis in the ischemic/reperfused region.

Key Words: 99mTc-annexin V • erythropoietin • reperfusion • apoptosis

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.